王廣，男，博士、主任醫師、教授、博士生導師。現任首都醫科大學附屬北京朝陽醫院內分泌科主任、國家代謝性疾病臨床醫學研究中心分中心主任。擔任中華醫學會內分泌學分會委員、中國內分泌代謝病聯盟委員、中國醫師協會內分泌代謝醫師分會委員，北京醫學會內分泌學分會副主任委員，北京內分泌代謝病學會糖尿病分會主任委員。主持國家自然科學基金5項，北京市自然科學基金重點項目、首都臨床特色基金等、首都醫學發展基金等。
基本介紹
人物經歷,科研成果,獲獎情況,擅長領域,出診時間,發表論文,
人物經歷
王廣，致力於糖尿病、肥胖、甲狀腺疾病的臨床與研究工作。對糖尿病心血管病變，妊娠甲狀腺疾病、榜祝肥胖、腎上腺疾病等有深入系統研究。課題組對糖尿病促進心血管疾病的機制研究、以及治療手段，處於國際先進水平。對甲狀采歡紙腺功能減退誘導心肌損傷，甲狀腺激素敏感性降低影響血脂紊亂及同型半胱氨酸代謝，加重心旬嬸禁血管損害地堡懂臭的研究成果，得到國內外認可。做為負責人，牽頭多項國際、國內多中心肥胖臨床研究，對肥胖狀態下內分泌激素的府轎蘭朽改變及調控，有深入的理解，在國際上首次報導肥胖患者脂肪組織胰島素抵抗與雄激素水平的研究。
科研成果
獲獎情況
2022年入選北京市登峰人才；
2016年入選第七屆“全國優秀科技工作者”；
2016年入選北京市“高創計畫”領軍人才；
2015年入選北京市百千萬人才工程市級人選。以第一完成人獲北京醫學科技獎。
擅長領域
擅長於糖尿病、甲狀腺疾病、肥胖、腎上腺疾病、垂體疾病、糖尿病心血管病、高脂血症只估判等內分泌複雜病的診斷與治療。
出診時間
內分泌科，星期二上午。
發表論文
成果發表在國際學術危符犁雜誌Nature Medicine (IF：87)、Metabolism (IF：13.9) 、Eur J Intern Med、J Clin Endocrinol Metab等。第一作者或通訊作者發表SCI論文80餘篇，累計影響因子500，被SCI引用2000餘次。
1. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat Med. 2018;24(12):1919-1929. (IF:87.21, Q1)
2. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy. Metabolism. 2015;64(3):380-390. (IF: 13.93, Q1)
3. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease. Metabolism. 2007;56(10):1396-1401. (IF: 13.93, Q1)
4. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty. Metabolism. 2005;54(5):590-597. (IF: 13.93, Q1)
5. Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus. Diabetes Metab. 2016;42(5):358-363. (IF: 8.254, Q1)
6. GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease. Diabetes Metab Res Rev. 2015;31(4):329-335. (IF: 8.128, Q1)
7. Levothyroxine treatment restored the decreased circulating fibroblast growth factor 21 levels in patients with hypothyroidism. Eur J Intern Med. 2016;31:94-98. (IF: 7.749)
8. Different Interactive Effects of Metformin and Acarbose with Dietary Macronutrient Intakes on Type 2 Diabetes Mellitus Patients Novel Findings from the MARCH Randomized Trial in China. Front Nutr, 2022, 9:861750. (IF: 6.590, Q1)
9. Impaired sensitivity to thyroid hormones is associated with elevated homocysteine levels in the euthyroid population. J Clin Endocrinol Metab. 2022. Dgac371 (IF:6.134, Q1)
10. Sex Differences in the Effect of Testosterone on Adipose Tissue Insulin Resistance from Overweight to Obese Adults. J Clin Endocrinol Metab. 2021. 106(8): 2252-2263 (IF:6.134, Q1)
4. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty. Metabolism. 2005;54(5):590-597. (IF: 13.93, Q1)
5. Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus. Diabetes Metab. 2016;42(5):358-363. (IF: 8.254, Q1)
6. GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease. Diabetes Metab Res Rev. 2015;31(4):329-335. (IF: 8.128, Q1)
7. Levothyroxine treatment restored the decreased circulating fibroblast growth factor 21 levels in patients with hypothyroidism. Eur J Intern Med. 2016;31:94-98. (IF: 7.749)
8. Different Interactive Effects of Metformin and Acarbose with Dietary Macronutrient Intakes on Type 2 Diabetes Mellitus Patients Novel Findings from the MARCH Randomized Trial in China. Front Nutr, 2022, 9:861750. (IF: 6.590, Q1)
9. Impaired sensitivity to thyroid hormones is associated with elevated homocysteine levels in the euthyroid population. J Clin Endocrinol Metab. 2022. Dgac371 (IF:6.134, Q1)
10. Sex Differences in the Effect of Testosterone on Adipose Tissue Insulin Resistance from Overweight to Obese Adults. J Clin Endocrinol Metab. 2021. 106(8): 2252-2263 (IF:6.134, Q1)
